MAYO CLINIC

The FDA approved acoramidis (Attruby), an oral transthyretin stabilizer for adults with ATTR-CM, reducing cardiovascular death and hospitalization. This first-of-its-kind therapy, designed to mimic a natural TTR gene mutation, was supported by the ATTRibute-CM trial, showing improved outcomes in ATTR-CM patients.

Cassava Sciences' Simufilam drug for Alzheimer’s failed a Phase 3 trial, leading to a 80% drop in shares. The company will discontinue another late-stage study and an open-label study of the drug.

BridgeBio Pharma received FDA approval for Attruby, an oral TTR stabiliser to reduce cardiovascular death and hospitalisation in ATTR-CM patients. The approval is based on the Phase 3 ATTRibute-CM study, which showed Attruby's efficacy and safety. BridgeBio plans global expansion and offers a patient support programme.

BridgeBio received FDA approval for Attruby (acoramidis), a near-complete TTR stabilizer for ATTR-CM, reducing cardiovascular death and hospitalization. Attruby, well-tolerated with mild side effects, significantly improved outcomes in the ATTRibute-CM Phase III study. BridgeBio will provide Attruby free for life to clinical trial participants and aims for global approvals.

Attruby, the first FDA-approved near-complete TTR stabilizer, significantly reduces cardiovascular death and hospitalizations in ATTR-CM patients, with rapid benefits seen in as few as 3 months. BridgeBio will provide Attruby free for life to U.S. clinical trial participants and offers extensive access programs. The company is set to receive $500 million under a royalty funding agreement and plans global expansion, with European approval expected in 2025.

Ascentage Pharma appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as independent non-executive directors, effective November 25, 2024.

Ten Delaware small businesses receive EDGE Grants, with five STEM companies each awarded up to $100,000 and five Entrepreneur Class businesses receiving up to $50,000. Recipients include biotech firms, a natural sweeteners producer, a valet trash service, and an Indo-Trini restaurant. The program aims to support small businesses and has provided $7.25 million to 110 businesses since 2019.

Experts criticize David Beckham's wellness brand IM8, calling its supplements 'meaningless nonsense' with 'questionable claims' based on 'limited information from poorly conducted studies'. The products, 'Daily Ultimate Essentials' and 'Daily Ultimate Longevity', are priced at £65 and £61 respectively, and despite claims of boosting energy, digestion, and skin health, experts warn of potential risks due to undisclosed ingredient quantities and possible allergic reactions.

AI is transforming healthcare, with 66% of clinicians recognizing its benefits and 38% already using it. AI aids in administrative tasks, diagnostic precision, and personalized patient care, potentially reducing burnout and improving outcomes. Privacy and security concerns are paramount, but AI's integration aims to enhance empathy and efficiency in healthcare delivery.

Delaware's EDGE Competition awards grants to ten small businesses, including LisenID, Natural Sweeteners, Nitro Biosciences, Otter Biotech, Rebisken, For Looks Studios, Good Company Handyman, Oath 84, Oceeto, and The Trash Porters, to support their growth in STEM and entrepreneurial fields.